Omnicell - OMCL Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OMCL shares.
View OMCL analyst ratings or view top-rated stocks.

8 brokers have issued twelve-month price targets for Omnicell's stock. Their OMCL share price forecasts range from $54.00 to $157.00. On average, they expect the company's share price to reach $82.44 in the next year. This suggests a possible upside of 58.4% from the stock's current price.
View analysts price targets for OMCL or view top-rated stocks among Wall Street analysts.

Omnicell's stock was trading at $180.44 at the beginning of the year. Since then, OMCL stock has decreased by 71.2% and is now trading at $52.05.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our OMCL earnings forecast.

Omnicell, Inc. (NASDAQ:OMCL) announced its earnings results on Tuesday, November, 2nd. The company reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.63 by $0.45. The business had revenue of $296.40 million for the quarter, compared to the consensus estimate of $283.82 million. Omnicell had a net margin of 3.67% and a trailing twelve-month return on equity of 9.74%. During the same quarter in the prior year, the firm posted $0.40 earnings per share.

Omnicell issued an update on its fourth quarter 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of $0.05-$0.15 for the period, compared to the consensus earnings per share estimate of $1.21. The company issued revenue guidance of $285.00 million-$295.00 million, compared to the consensus revenue estimate of $382.33 million.

150 employees have rated Omnicell Chief Executive Officer Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Omnicell's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.67%), Conestoga Capital Advisors LLC (3.77%), Macquarie Group Ltd. (2.73%), Lazard Asset Management LLC (2.48%), Geneva Capital Management LLC (2.18%) and Dimensional Fund Advisors LP (1.81%). Insiders that own company stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends.

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OMCL stock can currently be purchased for approximately $52.05.

Omnicell (NASDAQ:OMCL) has a market capitalization of $2.31 billion and generates $1.13 billion in revenue each year. The company earns $77.85 million in net income (profit) each year or $1.02 on an earnings per share basis.

The company employs 3,800 workers across the globe.

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is www.omnicell.com. The company can be reached via phone at (650) 251-6100, via email at ir@omnicell.com, or via fax at 847-596-3402.